The protective effect of conjugated linoleic acid (CLA) against IBD has been shown in vitro and in vivo to be mediated through PPARγ activation (22), although other n-PUFAs may antagonize the effects of CLA on PPARγ in experimental colitis (22). Here, PPARG is linked to inflammatory bowel disease.